A shelved Amgen drug that could drastically reduce or eliminate insulin injections that diabetes patients take is getting new life at a Camarillo biotechnology startup. In 2013, REMD Biotherapeutics resurrected an Amgen drug designed to treat Type 2 diabetes. Now, after more than 13 years of development, the drug known as REMD-477 is starting clinical…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
